Dr. Swan has worked for over twenty-five years to understand the threats posed by chemicals to our environment and our health, and, when necessary, to develop new paradigms to assess their risks. Of most concern to Dr. Swan are the chemicals that our bodies can confuse with its own hormones (the “endocrine disrupting” chemicals). At the Icahn School of Medicine at Mount Sinai, Department of Environmental Medicine and Public Health, Dr. Swan is working with a wide range of collaborators, including epidemiologists, biostatisticians, toxicologists, geneticists and systems biologists, to conduct studies and develop methods to evaluate the risks from such chemicals — methods that are sensitive enough to tease out the often subtle health effects of complex mixtures.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Swan did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.